Lys543
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.1
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys543  -  Ku80 (human)

Site Information
LFPLIEAkkkDQVTA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 12250514

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 2 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ) , mutation of modification site ( 2 ) , western blotting ( 2 )
Disease tissue studied:
bone cancer ( 2 ) , leukemia ( 5 , 6 ) , acute lymphocytic leukemia ( 5 ) , chronic myelogenous leukemia ( 6 ) , lung cancer ( 2 ) , non-small cell lung cancer ( 2 ) , lymphoma ( 4 ) , B cell lymphoma ( 4 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on Ku80:
molecular association, regulation ( 2 )
Effects of modification on biological processes:
DNA repair, induced ( 2 )
Inhibit interaction with:
DNA ( 2 )

References 

1

Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640
29967540   Curated Info

2

Ishida N, et al. (2017) Ubiquitylation of Ku80 by RNF126 Promotes Completion of Nonhomologous End Joining-Mediated DNA Repair. Mol Cell Biol 37
27895153   Curated Info

3

Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40
21906983   Curated Info

4

Guo A (2010) CST Curation Set: 9188; Year: 2010; Biosample/Treatment: cell line, SU-DHL-4/untreated; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

5

Guo A (2010) CST Curation Set: 9186; Year: 2010; Biosample/Treatment: cell line, Reh/untreated; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

6

Moritz A (2010) CST Curation Set: 9063; Year: 2010; Biosample/Treatment: cell line, K-562/Peroxide; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

7

Guo A (2009) CST Curation Set: 8644; Year: 2009; Biosample/Treatment: cell line, U266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

8

Possemato A (2009) CST Curation Set: 8247; Year: 2010; Biosample/Treatment: cell line, LNCaP/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

9

Possemato A (2009) CST Curation Set: 8243; Year: 2010; Biosample/Treatment: cell line, LNCaP/AAG; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info